Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-986447 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| BMS-986447 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| BMS-986447 | DRUG | Specified dose on specified days |
| Placebo | DRUG | Specified dose on specified days |
Inclusion Criteria: * Body mass index between 18 and 30 kilograms per metered square (kg/m\^2), inclusive. * Healthy male and female participants without clinically significant deviation from normal in medical history, physical examination, ECG, and clinical laboratory determinations. * A negative ...
BMS-986447 is an investigational small molecule drug being developed by Bristol-Myers Squibb Company (ticker: BMY). It has been studied in a Phase 1 clinical trial in healthy participants. The therapeutic indication for BMS-986447 has not been disclosed.
BMS-986447 is being developed by Bristol-Myers Squibb Company, which trades under the ticker BMY. Bristol-Myers Squibb sponsored the Phase 1 study of BMS-986447 conducted in the United States.
BMS-986447 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. One Phase 1 trial of BMS-986447 has been completed, and no trials of the drug are currently active.
BMS-986447 has been evaluated in one clinical trial, NCT05760937, titled A Study to Evaluate the Safety, Tolerability and Drug Levels of BMS-986447 in Healthy Participants. The Phase 1 trial enrolled 32 healthy participants in the United States and is completed.
The Phase 1 trial of BMS-986447, NCT05760937, was a randomized, double-blind, placebo-controlled study in healthy participants aged 18 years and older. It enrolled 32 participants in the United States and assessed safety, tolerability, and drug levels of BMS-986447.